APL-1202 in combination with tislelizumab for Bladder Cancer
Study Summary
This trial is testing a new combination therapy for patients with bladder cancer who are ineligible or refuse cisplatin-based chemotherapy.
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is enrollment for this research still ongoing?
"As indicated by clinicaltrials.gov, this medical study is still open for recruitment as of today. It was initially posted on December 28th 2021 and has been updated more recently on February 21st 2022."
Is there precedent for this kind of clinical trial?
"As of present, there are 105 active trials for APL-1202 combined with tislelizumab in 426 cities and 45 nations. The first trial was conducted by BeiGene in 2017 and involved 805 participants who completed its Phase 3 approval phase. Following the initial run, a further 11 studies have been concluded."
How many participants are being incorporated in this research experiment?
"Affirmative. Clinicaltrials.gov presents evidence that this research is in the midst of recruitment, with 79 volunteers sought from 1 site since its first posting on December 28th 2021 and last editing on February 21st 2022."
What is the major goal of this clinical test?
"This protocol will track two primary outcomes over a 26 month period: adverse events (AE) and serious adverse events (SAE). Secondary measurements include Tmax, Ae%, and plasma ctDNA-based tumor mutation burdens (TMB)."
Are there any other investigations conducted regarding the concomitant use of APL-1202 and tislelizumab?
"At present, there are 105 active clinical trials for APL-1202 and tislelizumab therapy, with 18 of those studies in their final phase. Trials are being conducted mainly in Nanning, Guangxi; however, 2329 other locations also have these experiments underway."